Quarterly report pursuant to Section 13 or 15(d)

Other Income / (Expense)

Other Income / (Expense)

6 Months Ended

Dec. 31, 2023

Note 11. Other Income / (Expense):

The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows (in thousands):


	Quarter Ended					Six Months Ended
	December 31,					December 31,
	2023		2022		2023		2022
Interest expense	$	(4,329)	$	(2,356)	$	(9,222)	$	(6,146)
Interest income		816		968		1,706		1,401
Gain (loss) on investment⁽¹⁾		—		—		283		49,695
Gain (loss) on equity method investment		(1,914)		—		(4,204)		—
Other non-operating income (expense), net		810		(74)		516		988
Total other income (expense)	$	(4,617)	$	(1,462)	$	(10,921)	$	45,938

⁽¹⁾Primarily due to a $0.3 million gain on the sale of our exchange traded investment grade bond funds during the six months ended December 31, 2023 compared to a $37.2 million gain on the sale of our ChemoCentryx investment and a $11.7 million gain on the sale of Eminence in the six months ended December 31, 2022.